LIANY

SEC source: 0000899243-22-000126 · doc4.xml · nonDerivative · entry 1

QIAN JIANG · CIK 0001880938 · China General Manager

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,588

F1 · shares: Represents restricted share units granted to the Reporting Person under the LianBio 2021 Equity Incentive Plan. Each restricted share unit represents the contingent right to receive one share of the Issuer's Ordinary Shares. 25% of the restricted share units shall vest on December 31, 2022; the remainder shall vest in 25% annual installments such that the restricted share units are fully vested on December 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000899243-22-000135 · doc4.xml · derivative · entry 3

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,647

Underlying: Ordinary Shares · 36,548 shares

Expires 2030-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares underlying the option vested and became exercisable on the first anniversary of the commencement date, December 17, 2021; the remainder shall vest and become exercisable in 3 equal annual installments such that the option shall be fully vested on December 17, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000899243-22-000135 · doc4.xml · nonDerivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,548

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-046751 · doc4.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,202,841

Underlying: Ordinary Shares · 5,996 shares

Expires 2031-12-01

F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest and become exercisable on December 1, 2022; the remainder shall vest and become exercisable in three equal annual installments such that the option shall be fully vested on December 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000899243-21-042807 · doc4.xml · derivative · entry 12

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Ordinary Shares · 2,477,005 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date.

F5 · price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date.

F5 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date.

F5 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date.

F4 · ownership.nature: The securities are directly held by C2 Life Sciences LLC ("C2 Life"). The Advisor serves as the investment advisor to C2 Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042807 · doc4.xml · derivative · entry 11

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Ordinary Shares · 2,923,900 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F6 · derivative.exercise_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F6 · derivative.expiration_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F3 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund, LP ("Perceptive Xontogeny"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment advisor to Perceptive Xontogeny and is an affiliate of the Advisor. Joseph Edelman is the managing member of the Advisor. The Venture Advisor, the Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042807 · doc4.xml · derivative · entry 10

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Ordinary Shares · 14,619,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F6 · derivative.exercise_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F6 · derivative.expiration_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F2 · ownership.nature: The securities are directly held by LEV LB Holdings, LP ("LEV LB"). LEV LB Holdings GP, LLC ("LEV LB LLC") is the manager of LEV LB. Mr. Edelman is the sole member of LEV LB LLC. LEV LB LLC and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042807 · doc4.xml · derivative · entry 9

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Ordinary Shares · 14,619,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F6 · derivative.exercise_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F6 · derivative.expiration_date: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042807 · doc4.xml · derivative · entry 8

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,715,510 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date.

F5 · price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date.

F5 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date.

F5 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date.

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 7

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,477,005

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date.

F4 · ownership.nature: The securities are directly held by C2 Life Sciences LLC ("C2 Life"). The Advisor serves as the investment advisor to C2 Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 6

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,330,675

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F3 · ownership.nature: The securities are directly held by Perceptive Xontogeny Venture Fund, LP ("Perceptive Xontogeny"). Perceptive Venture Advisors, LLC (the "Venture Advisor") serves as the investment advisor to Perceptive Xontogeny and is an affiliate of the Advisor. Joseph Edelman is the managing member of the Advisor. The Venture Advisor, the Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 5

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 21,653,385

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F2 · ownership.nature: The securities are directly held by LEV LB Holdings, LP ("LEV LB"). LEV LB Holdings GP, LLC ("LEV LB LLC") is the manager of LEV LB. Mr. Edelman is the sole member of LEV LB LLC. LEV LB LLC and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 4

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 25,588,895

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Each share of the Issuer's Seed Series Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Seed Series Preferred Shares have no expiration date.

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 3

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 10,969,395

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Each share of the Issuer's Series A Preferred Shares automatically converted into 5.8478 of the Issuer's Ordinary Shares immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Shares have no expiration date.

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001062993-21-010295 · form4.xml · nonDerivative · entry 2

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · Director · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · Director · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · Director · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 27,858,895

F5 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.50 to $13.57, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001062993-21-010295 · form4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · Director · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · Director · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · Director · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · Director · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · Director · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 27,838,895

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 2

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 7,253,885

F7 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.79, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042807 · doc4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

LEV LB Holdings, LP · CIK 0001789443 · 10% owner

Perceptive Xontogeny Venture Fund, LP · CIK 0001757940 · 10% owner

C2 Life Sciences LLC · CIK 0001890152 · 10% owner

Perceptive Venture Advisors, LLC · CIK 0001890130 · 10% owner

LEV LB Holdings GP, LLC · CIK 0001890132 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 7,153,885

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. ("Perceptive Life"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to Perceptive Life. Joseph Edelman is the managing member of the Advisor. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-042216 · doc4.xml · derivative · entry 1

Jahn Brianne · CIK 0001885012 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 915,722

Underlying: Ordinary Shares · 330,942 shares

Expires 2031-10-31

F1 · derivative.exercise_date: 1/4 of the shares underlying the option will vest and become exercisable on October 31, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on October 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000899243-21-042211 · doc4.xml · derivative · entry 1

Yu Debra · CIK 0001869480 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,747,174

Underlying: Ordinary Shares · 747,227 shares

Expires 2031-10-31

F1 · derivative.exercise_date: 1/4 of the shares underlying the option will vest and become exercisable on October 31, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on October 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000899243-21-042220 · doc4.xml · derivative · entry 1

QIAN JIANG · CIK 0001880938 · China General Manager

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 409,343

Underlying: Ordinary Shares · 409,343 shares

Expires 2031-10-31

F1 · derivative.exercise_date: 1/4 of the shares underlying the option will vest and become exercisable on October 31, 2022; the remainder shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on October 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000899243-21-042219 · doc4.xml · derivative · entry 1

Silbermann Susan Michele · CIK 0001887214 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,600

Underlying: Ordinary Shares · 72,600 shares

Expires 2031-10-31

F1 · derivative.exercise_date: 1/36 of the shares underlying the option vested and became exercisable on October 31, 2021; the remainder shall vest and become exercisable in 35 equal monthly installments such that the option shall be fully vested on October 31, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000899243-21-042215 · doc4.xml · derivative · entry 1

Wu Jesse · CIK 0001730238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,600

Underlying: Ordinary Shares · 72,600 shares

Expires 2031-10-31

F1 · derivative.exercise_date: 1/36 of the shares underlying the option vested and became exercisable on October 31, 2021; the remainder shall vest and become exercisable in 35 equal monthly installments such that the option shall be fully vested on October 31, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000899243-21-042213 · doc4.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,196,845

Underlying: Ordinary Shares · 229,538 shares

Expires 2031-10-31

F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest and become exercisable on October 31, 2022; the remainder shall vest and become exercisable in three equal annual installments such that the option shall be fully vested on October 31, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.